Why a Malvern biopharma is exploring combining its lead drug candidate targeting Alzheimer's and Parkinson's diseases with a ...

Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Here, Hancock cites fund holding Eli Lilly and its patents on GLP-1 weight loss drugs Mounjaro and Zepbound. Hancock expects ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

ELI LILLY Inc. LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.